Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H9F3N2O2 |
Molecular Weight | 282.2185 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc(cc(c1)Nc2c(cccn2)C(=O)O)C(F)(F)F
InChI
InChIKey=JZFPYUNJRRFVQU-UHFFFAOYSA-N
InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
Niflumic acid belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDs) and used in the treatment of rheumatoid arthritis, and joint and muscular pain. Its mechanism of action is believed to be based on selective inhibition of cycloxygenases-2 that results in antipyretic, analgesic, and anti-inflammatory effects. In addition to these effects on prostaglandin synthesis, it has been shown to act as a positive allosteric modulator on α1β2γ2 and as a negative modulator on α6β2 and α6β2γ2 (and α1β2) GABAA receptors. In addition, was reported, that niflumic acid blocked T-type calcium channels. It is available for clinical use in several European countries.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7947975 |
0.1 µM [IC50] | ||
Target ID: CHEMBL2095172 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12920213 |
|||
Target ID: CHEMBL2111370 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12920213 |
|||
Target ID: CHEMBL2362995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21898399 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | niflamol Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Ca(2+)-activated Cl(-) channels: a newly emerging anion transport family. | 2001 |
|
Evidence for two mechanisms of amino acid osmolyte release from hippocampal slices. | 2001 Aug |
|
The disulfonic stilbene DIDS and the marine poison maitotoxin activate the same two types of endogenous cation conductance in the cell membrane of Xenopus laevis oocytes. | 2001 Aug |
|
Responses to prolonged odour stimulation in frog olfactory receptor cells. | 2001 Jul 1 |
|
Niflumic acid modulates uncoupled substrate-gated conductances in the human glutamate transporter EAAT4. | 2001 Jul 1 |
|
Chloride channel antagonists perturb growth and morphology of Neurospora crassa. | 2001 Jul 24 |
|
Role of Cl- current in endothelin-1-induced contraction in rabbit basilar artery. | 2001 Nov |
|
Characterization of action potential-evoked calcium transients in mouse postganglionic sympathetic axon bundles. | 2001 Nov 15 |
|
Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. | 2001 Nov 9 |
|
Ca2+-dependent membrane currents in vascular smooth muscle cells of the rabbit. | 2001 Oct 12 |
|
Volume-activated trimethylamine oxide efflux in red blood cells of spiny dogfish (Squalus acanthias). | 2001 Sep |
|
Multiple transport functions of a red blood cell anion exchanger, tAE1: its role in cell volume regulation. | 2001 Sep 1 |
|
Synthesis, spectral studies and anti-inflammatory activity of glycolamide esters of niflumic acid as potential prodrugs. | 2002 |
|
Action potential afterdepolarization mediated by a Ca2+-activated cation conductance in myenteric AH neurons. | 2002 |
|
The non-steroidal anti-inflammatory drug niflumic acid inhibits Candida albicans growth. | 2002 |
|
Enhancement of HCO(3)(-) permeability across the apical membrane of bovine corneal endothelium by multiple signaling pathways. | 2002 Apr |
|
Calcium and calcium-activated currents in vagotomized rat primary vagal afferent neurons. | 2002 Apr 15 |
|
The DC electrical-field-induced Ca(2+) response and growth stimulation of multicellular tumor spheroids are mediated by ATP release and purinergic receptor stimulation. | 2002 Aug 15 |
|
Characterisation of the ionic currents in freshly isolated rat ureter smooth muscle cells: evidence for species-dependent currents. | 2002 Dec |
|
Differential activation of ion channels by inositol 1,4,5-trisphosphate (IP3)- and ryanodine-sensitive calcium stores in rat basilar artery vasomotion. | 2002 Dec 1 |
|
Comparative inhibitory effects of niflumic acid and novel synthetic derivatives on the rat isolated stomach fundus. | 2002 Feb |
|
Dual effect of blocking agents on Ca2+-activated Cl(-) currents in rabbit pulmonary artery smooth muscle cells. | 2002 Feb 15 |
|
Comparison of the osmolyte transport properties induced by trAE1 versus IClswell in Xenopus oocytes. | 2002 Jan 1 |
|
Swelling-activated taurine and creatine effluxes from rat cortical astrocytes are pharmacologically distinct. | 2002 Jan 15 |
|
Inhibition of gap junction hemichannels by chloride channel blockers. | 2002 Jan 15 |
|
Role of Ca2+-activated Cl- channels and MLCK in slow IJP in opossum esophageal smooth muscle. | 2002 Jul |
|
Presence of a calcium-activated chloride current in mouse ventricular myocytes. | 2002 Jul |
|
A comparative study of the effects of Cl(-) channel blockers on mesenteric vascular conductance in anaesthetized rat. | 2002 Jul 12 |
|
Disparity between ionic mediators of volume regulation and apoptosis in N1E 115 mouse neuroblastoma cells. | 2002 Jul 12 |
|
The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. | 2002 Jun |
|
Control of descending vasa recta pericyte membrane potential by angiotensin II. | 2002 Jun |
|
Does mucus hypersecretion matter in airway disease? | 2002 Jun 1 |
|
Activation thresholds of K(V), BK andCl(Ca) channels in smooth muscle cells in pial precapillary arterioles. | 2002 Mar-Apr |
|
D2-like dopamine receptors promote interactions between calcium and chloride channels that diminish rod synaptic transfer in the salamander retina. | 2002 May-Jun |
|
[BK channels play an important role as a negative feedback mechanism in the regulation of spontaneous rhythmic contraction of urinary bladder smooth muscles]. | 2002 Nov |
|
Anion channels influence ECC by modulating L-type Ca(2+) channel in ventricular myocytes. | 2002 Nov |
|
[Cannabis and nifluril]. | 2002 Nov-Dec |
|
Plasmalemmal voltage-activated K(+) currents in protoplasts from tobacco BY-2 cells: possible regulation by actin microfilaments? | 2002 Oct |
|
Tyrosine kinases and amino acid efflux under hyposmotic and ischaemic conditions in the chicken retina. | 2002 Oct |
|
Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes. | 2002 Oct 11 |
|
Functional role of Cl- channels in acidic pH-induced contraction of the aorta of spontaneously hypertensive and Wistar Kyoto rats. | 2002 Oct 25 |
|
Three electrophysiological phenotypes of cultured human umbilical vein endothelial cells. | 2002 Sep |
|
Oscillatory chloride efflux at the pollen tube apex has a role in growth and cell volume regulation and is targeted by inositol 3,4,5,6-tetrakisphosphate. | 2002 Sep |
|
Characterization of norepinephrine-evoked inward currents in interstitial cells isolated from the rabbit urethra. | 2002 Sep |
|
Separation of two Cl(-) currents in cultured human and murine mesangial cells: biophysical and pharmacological characteristics of I(Cl.vol) and I(Cl.Ca). | 2002 Sep-Oct |
|
Ca2+-activated Cl- current in cultured myenteric neurons from murine proximal colon. | 2003 Apr |
|
Anomalous effect of anthracene-9-carboxylic acid on calcium-activated chloride currents in rabbit pulmonary artery smooth muscle cells. | 2003 Jan |
|
Cellular mechanisms involved in the increased contraction of portal veins from Schistosoma mansoni-infected mice. | 2003 Jan |
|
Ca2+-activated Cl- channels in corpus cavernosum smooth muscle: a novel mechanism for control of penile erection. | 2003 Jan |
|
Effects of osmotic changes on the chemoreceptor cell of rat carotid body. | 2003 Jan 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6852999
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16528019
Niflumic acid (100 uM) inhibits not only IL-13-induced goblet cell hyperplasia but also airway hyperresponsiveness and eosinophilic infiltration. IL-13 instillation markedly enhanced the expression of MUC5AC mRNA in the lung, and niflumic acid treatment suppressed IL-13–induced overexpression of MUC5AC. Effects of niflumic acid on MUC5AC expression were also analyzed after single IL-13 instillation, and niflumic acid suppressed overexpression of MUC5AC 24 h after IL-13.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M02AA17
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
||
|
WHO-VATC |
QM01AX02
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
||
|
WHO-VATC |
QM01AX52
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
||
|
WHO-VATC |
QM02AA17
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
||
|
WHO-ATC |
M01AX02
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2194
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
C76807
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
4488
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
2439
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
CHEMBL63323
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
D009544
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
7418
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | RxNorm | ||
|
4394-00-7
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
224-516-2
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
4U5MP5IUD8
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
SUB09257MIG
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
NIFLUMIC ACID
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
4394-00-7
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
M7885
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | Merck Index | ||
|
1925
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY | |||
|
DB04552
Created by
admin on Fri Jun 25 21:10:46 UTC 2021 , Edited by admin on Fri Jun 25 21:10:46 UTC 2021
|
PRIMARY |
ACTIVE MOIETY